Plasma blood transfusion may contain therapeutic antibodies to treat immunocompromised COVID-19 patients, a new study has concluded.
The peer-reviewed study, published on Thursday in the journal Jama Network Open, states that the research is important because people diagnosed with COVID-19 who are also immunocompromised “have increased risk for morbidity and mortality associated with the disease.”
Researchers analyzed “three randomized clinical trials, five cohort studies, 13 uncontrolled large case series, and 125 case report series,” the study says.
Overall, the study included an analysis of over 2,100 participants.
All data collected were extracted by three independent reviewers, according to the study.
Last August, a search was performed for COVID clinical studies of convalescent plasma use in immunocompromised patients.
More recent COVID research
A recent study saw that immune systems of men who had recovered from mild cases of COVID responded more robustly to flu vaccines than women.
Another study from last month saw that some people who tested positive for COVID-19 do not get their sense of smell back due to a declining number of olfactory nerve cells caused by an ongoing immune assault.
Judy Siegel-Itzkovich contributed to this report.
